NEW YORK ( The Deal) -- Tony Zook is facing major headwinds in his effort to steer the fortunes of Vivus (VVUS - Get Report), and crucial to that effort is bringing the right licensing partner on board to help commercialize its weight-loss drug Qsymia."A large pharmaceutical partner is critical to realize the full potential of [the Qsymia] franchise and to build the market. To date we've made good progress in this area," Zook, Vivus' new CEO, said during the company's second quarter sales and earnings conference call with investors held late Tuesday, Aug. 7.
The Deal: Vivus Considers Next Steps With Big Pharma Partners
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.